Total trials
730
Active
87
Phase 3
70
Total enrollment
186,142
Pipeline matrix
Showing 34 of 34 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| N acetyl cysteine | — | — | — | — | 2 | ||
| Beta-lactam monotherapy | — | — | — | — | — | 1 | |
| Beta-lactam plus levofloxacin combination therapy | — | — | — | — | — | 1 | |
| Pertagen® vaccine | — | — | — | — | — | 1 | |
| Adacel® vaccine | — | — | — | — | — | 1 | |
| Nitrofurantoin | — | — | — | — | — | 1 | |
| Gynoflor | — | — | — | — | — | 1 | |
| Lemborexant | — | — | — | — | — | 1 | |
| tenecteplase | — | — | — | — | — | 1 | |
| PRP | — | — | — | — | — | 1 | |
| Bupivacaine | — | — | — | — | 4 | ||
| Branched-chain amino acid | — | — | — | — | 3 | ||
| olanzapine 5 mg | — | — | — | — | — | 2 | |
| Trelegy or Anoro | — | — | — | — | — | 1 | |
| olanzapine | — | — | — | — | — | 1 | |
| Rifaximin | — | — | — | — | — | 1 | |
| Concurrent chemotherapy | — | — | — | — | — | 1 | |
| Human Albumin 20% Solution | — | — | — | — | — | 1 | |
| Olanzapine 2.5 MG | — | — | — | — | — | 1 | |
| Holy basil extract | — | — | — | — | — | 1 | |
| Aminophylline | — | — | — | — | — | 1 | |
| Strengthening training with biofeedback | — | — | — | — | — | 1 | |
| Endurance training with biofeedback | — | — | — | — | — | 1 | |
| Wharton's jelly-derived mesenchymal stem cells | — | — | — | — | — | 1 | |
| 0.9 % Normal Saline | — | — | — | — | — | 1 | |
| GMP compliant-BM-MSC derived sEVs | — | — | — | — | — | 1 | |
| TetraFluvac TF vaccine | — | — | — | — | — | 1 | |
| Vaxigrip vaccine | — | — | — | — | — | 1 | |
| dexamethasone sparing | — | — | — | — | — | 1 | |
| rDEN2Δ30-7169 | — | — | — | — | — | 2 | |
| Tranexamic acid | — | — | — | — | 4 | ||
| Vancomycin | — | — | — | — | — | 1 | |
| Lidocaine 2% and Methylprednisolone 80 mg | — | — | — | — | — | 1 | |
| Standard systemic treatment for advanced lung cancer | — | — | — | — | — | 1 |
Next readouts
- 2024-03-25
- 2024-09-18
- 2025-08-01
- 2025-08-31
- 2025-09-23
- 2026-01
- 2026-01-10
- 2026-01-21
- 2026-02-24
- 2026-03
Top conditions
- Septic Shock13
- Stroke10
- Pain, Postoperative9
- Postoperative Pain9
- Pain9
- Critical Illness8
- Asthma7
- Cesarean Section Complications6
Frequently asked questions about Mahidol University
- How many clinical trials does Mahidol University have on ClinicalTrials.gov?
- Mahidol University is listed as the lead sponsor on 730 clinical trials in ClinicalTrials.gov, 87 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Mahidol University's trials are in Phase 3?
- 70 of Mahidol University's trials are in Phase 3, spread across 34 active drug programs.
- What therapeutic areas does Mahidol University focus on?
- Mahidol University's most-studied conditions on ClinicalTrials.gov are Septic Shock, Stroke, Pain, Postoperative, Postoperative Pain, Pain.
- When are Mahidol University's next clinical trial readouts?
- Mahidol University has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais”, expected around 2024-03-25.